Non-alcoholic Steatohepatitis Clinical Trials Market (By Phase: Phase I, Phase II, Phase III, Phase IV; By Study Design: Interventional, Observational, Expanded Access) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Non-alcoholic Steatohepatitis Clinical Trials Market, By Study Design

7.1.  Non-alcoholic Steatohepatitis Clinical Trials Market, by Study Design, 2021-2030

7.1.1.    Interventional

7.1.1.1.        Market Revenue and Forecast (2019-2030)

7.1.2.    Observational

7.1.2.1.        Market Revenue and Forecast (2019-2030)

7.1.3.    Expanded Access

7.1.3.1.        Market Revenue and Forecast (2019-2030)

Chapter 8.  Global Non-alcoholic Steatohepatitis Clinical Trials Market, By Phase

8.1.  Non-alcoholic Steatohepatitis Clinical Trials Market, by Phase, 2021-2030

8.1.1.    Phase I

8.1.1.1.        Market Revenue and Forecast (2019-2030)

8.1.2.    Phase II

8.1.2.1.        Market Revenue and Forecast (2019-2030)

8.1.3.    Phase III

8.1.3.1.        Market Revenue and Forecast (2019-2030)

8.1.4.    Phase IV

8.1.4.1.        Market Revenue and Forecast (2019-2030)

Chapter 9.  Global Non-alcoholic Steatohepatitis Clinical Trials Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Study Design (2019-2030)

9.1.2.    Market Revenue and Forecast, by Phase (2019-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.1.3.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.1.4.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Study Design (2019-2030)

9.2.2.    Market Revenue and Forecast, by Phase (2019-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.2.3.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.2.4.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.2.5.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.2.6.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Study Design (2019-2030)

9.3.2.    Market Revenue and Forecast, by Phase (2019-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.3.3.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.3.4.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.3.5.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.3.6.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Study Design (2019-2030)

9.4.2.    Market Revenue and Forecast, by Phase (2019-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.4.3.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.4.4.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.4.5.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.4.6.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Study Design (2019-2030)

9.5.2.    Market Revenue and Forecast, by Phase (2019-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.5.3.2.        Market Revenue and Forecast, by Phase (2019-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Study Design (2019-2030)

9.5.4.2.        Market Revenue and Forecast, by Phase (2019-2030)

Chapter 10.  Company Profiles

10.1.              Pfizer Inc.

10.1.1.  Company Overview

10.1.2.  Study Design Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Novartis AG

10.2.1.  Company Overview

10.2.2.  Study Design Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Icon Plc

10.3.1.  Company Overview

10.3.2.  Study Design Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              LabCorp

10.4.1.  Company Overview

10.4.2.  Study Design Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Allergan Plc

10.5.1.  Company Overview

10.5.2.  Study Design Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Cadila Healthcare Ltd.

10.6.1.  Company Overview

10.6.2.  Study Design Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Shire Plc (Takeda Pharmaceuticals)

10.7.1.  Company Overview

10.7.2.  Study Design Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Eli Lilly

10.8.1.  Company Overview

10.8.2.  Study Design Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Novo Nordisk

10.9.1.  Company Overview

10.9.2.  Study Design Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           Gilead Sciences Inc.

10.10.1.               Company Overview

10.10.2.               Study Design Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

Glossary of Terms

Report Detail

Proceed To Buy

USD 4500
USD 7900